- Home
- ARMN vs ADPT Comparison
ARMN vs ADPT Comparison
Compare ARMN & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- ADPT
- Stock Information
- Founded
- ARMN 1992
- ADPT 2009
- Country
- ARMN Canada
- ADPT United States
- Employees
- ARMN N/A
- ADPT N/A
- Industry
- ARMN
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARMN
- ADPT Health Care
- Exchange
- ARMN Nasdaq
- ADPT Nasdaq
- Market Cap
- ARMN 834.4M
- ADPT 685.7M
- IPO Year
- ARMN N/A
- ADPT 2019
- Fundamental
- Price
- ARMN $4.46
- ADPT $5.52
- Analyst Decision
- ARMN
- ADPT Buy
- Analyst Count
- ARMN 0
- ADPT 5
- Target Price
- ARMN N/A
- ADPT $7.00
- AVG Volume (30 Days)
- ARMN 1.3M
- ADPT 1.1M
- Earning Date
- ARMN 11-13-2024
- ADPT 11-07-2024
- Dividend Yield
- ARMN N/A
- ADPT N/A
- EPS Growth
- ARMN N/A
- ADPT N/A
- EPS
- ARMN 0.09
- ADPT N/A
- Revenue
- ARMN $466,257,000.00
- ADPT $168,766,000.00
- Revenue This Year
- ARMN $46.47
- ADPT $3.47
- Revenue Next Year
- ARMN N/A
- ADPT $20.01
- P/E Ratio
- ARMN $59.80
- ADPT N/A
- Revenue Growth
- ARMN 15.56
- ADPT N/A
- 52 Week Low
- ARMN $2.16
- ADPT $2.28
- 52 Week High
- ARMN $5.16
- ADPT $5.56
- Technical
- Relative Strength Index (RSI)
- ARMN 44.84
- ADPT 66.70
- Support Level
- ARMN $4.56
- ADPT $4.83
- Resistance Level
- ARMN $4.74
- ADPT $5.20
- Average True Range (ATR)
- ARMN 0.16
- ADPT 0.39
- MACD
- ARMN -0.05
- ADPT 0.09
- Stochastic Oscillator
- ARMN 3.39
- ADPT 97.78
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development and operation of gold properties in Colombia, Guyana and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, Toroparu Project in Guyana and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).